CON: Not All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Works matching IS 19414390 AND DT 2011 AND VI 4 AND IP 2
Results: 8
1
2
CON: Systemic Therapy for All Endometrial Carcinomas Should Not be Paclitaxel Plus Carboplatin.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
3
PRO: Systemic Therapy for All Endometrial Cancers Should be Paclitaxel Plus Carboplatin.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
4
CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
5
CON: Patients With Recurrent Ovarian Carcinoma Should Not be Treated With Antiangiogenic Agents in Combination With Chemotherapy.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
6
CON: Therapy for a Patient With PlatinumSResistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
7
PRO: Patients With Endometrial Carcinoma Involving Extrauterine Disease Should, After Any Indicated Surgery, Receive Chemotherapy.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
8
PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article